10x Genomics (TXG) Operating Leases (2020 - 2026)

10x Genomics has disclosed Operating Leases across 7 years of filings, most recently posting $81.4 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $81.4 million, up 1.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.4 million (up 1.64% YoY), and the FY2025 annual result was $73.4 million, changed 0.07% from the prior year.
• Operating Leases came in at $81.4 million for Q1 2026 at 10x Genomics, up from $73.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $99.0 million in Q2 2022 to a low of $73.3 million in Q4 2024.
• The 5-year median for Operating Leases is $86.1 million (2022), against an average of $85.8 million.
• Across the five-year window, Operating Leases jumped 50.21% in 2022 and fell 13.13% in 2025, its largest moves.
• 10x Genomics' Operating Leases stood at $86.1 million in 2022, then slipped by 2.66% to $83.8 million in 2023, then retreated by 12.55% to $73.3 million in 2024, then grew by 0.07% to $73.4 million in 2025, then climbed by 10.92% to $81.4 million in 2026.
• The last three Operating Leases figures came in at $81.4 million (Q1 2026), $73.4 million (Q4 2025), and $87.0 million (Q3 2025), per Business Quant data.